Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-11-30

FDA Approved: ADALIMUMAB — Supplemental Application (CELLTRION USA, Inc.)

View source ↗

Summary

The FDA approved a supplemental Biologics License Application for the adalimumab biosimilar ADALIMUMAB-AATY from Celltrion USA, Inc., allowing its use for the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ADALIMUMAB-AATY (adalimumab)

Snippet

SUPPL AP for ADALIMUMAB (ADALIMUMAB-AATY)